AI Revolutionizes Antibody Discovery: Fast, Unimagined Molecules Unveiled

LabGenius, a company based in South London, is using AI and automation to revolutionize the process of engineering new medical antibodies. By employing machine learning algorithms and automated robotic systems, LabGenius can quickly explore the vast space of potential antibody designs, selecting and testing hundreds of options to find potentially fruitful areas for further investigation. This automated approach yields unexpected solutions and significantly speeds up the drug discovery process, potentially leading to more effective antibody treatments with fewer side effects. LabGenius has raised $28 million in funding and is beginning to partner with pharmaceutical companies.